Kestra Medical Technologies (KMTS) Proxy filing summary

Executive summary

• The annual meeting will be held virtually on September 9, 2026, with shareholders able to vote and submit questions online.

• Shareholders of record as of July 17, 2026, are entitled to vote on the election of directors and ratification of the auditor.

• The company is classified as an emerging growth company and follows reduced disclosure requirements.

• Forward-looking statements are included, with risks detailed in the annual report.

Voting matters and shareholder proposals

• Shareholders will vote on electing three Class II directors for terms expiring in 2029 and ratifying PricewaterhouseCoopers LLP as the independent auditor for fiscal 2027.

• Board recommends voting FOR all director nominees and FOR auditor ratification.

• Shareholders may submit proposals for the 2027 meeting by March 30, 2027, and nominate directors per company bye-laws.

Board of directors and corporate governance

• The board consists of eight members divided into three staggered classes, with declassification planned after 2031.

• Board committees include audit, compensation, and nominating/governance, all composed of independent directors except for the CEO and General Counsel.

• The board conducts annual leadership assessments and maintains a code of conduct and governance guidelines.

• Board chair and CEO roles are separated for effective oversight.